|
|
Home
Search
Study Topics
Glossary
|
 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|||||||||||||||||||||||||||||||||||||||||||||
| Sponsored by: |
Teva Pharmaceutical Industries |
|---|---|
| Information provided by: | Teva Pharmaceutical Industries |
| ClinicalTrials.gov Identifier: | NCT00203008 |
Purpose
Patients with Parkinson's disease will be seen by a dermatologist who will biopsy any suspicious skin lesions.
| Condition |
|---|
|
Parkinsons Disease Malignant Melanoma |
| Study Type: | Observational |
| Official Title: | A Survey to Assess the Incidence and Characteristics of Melanoma in Parkinson's Disease Patients |
Eligibility| Genders Eligible for Study: | Both |
| Accepts Healthy Volunteers: | No |
Inclusion Criteria:
Confirmed diagnosis Parkinson's disease Patient able and willing to give informed consent Patient must not be taking any investigational drug at the time of enrollment
Exclusion Criteria:
Contacts and Locations| United States, California | |
| The Parkinson's & Movement Disorder Institute | |
| Fountain Valley, California, United States, 92708 | |
| United States, Georgia | |
| Emory University | |
| Atlanta, Georgia, United States, 30329 | |
| United States, Nebraska | |
| Creighton University | |
| Omaha, Nebraska, United States, 68131 | |
| United States, New York | |
| Long Island Jewish Medical Center | |
| New Hyde Park, New York, United States, 11040 | |
| United States, Pennsylvania | |
| Pennsylvania Hospital | |
| Philadelphia, Pennsylvania, United States, 19107 | |
| United States, Rhode Island | |
| Memorial Hospital of Rhode Island | |
| Pawtucket, Rhode Island, United States, 02860 | |
| United States, Virginia | |
| University of Virginia Health System | |
| Charlottesville, Virginia, United States, 22908 | |
| Canada, Quebec | |
| CHUM-Hotel-Dieu | |
| Montreal, Quebec, Canada, H2w1T8 | |
| Study Director: | Bruce Schwartz, Ph.D. | Teva Neuroscience, Inc. |
More Information
| Responsible Party: | Teva Neuroscience ( J. Michael Nicholas, PhD, Sr. Director ) |
| Study ID Numbers: | EP002 |
| Study First Received: | September 13, 2005 |
| Last Updated: | December 11, 2007 |
| ClinicalTrials.gov Identifier: | NCT00203008 |
| Health Authority: | United States: Food and Drug Administration |
|
Ganglion Cysts Basal Ganglia Diseases Central Nervous System Diseases Neurodegenerative Diseases Brain Diseases Melanoma Neuroendocrine Tumors Neuroectodermal Tumors |
Parkinson Disease Movement Disorders Neoplasms, Germ Cell and Embryonal Nevus, Pigmented Neuroepithelioma Nevus Parkinsonian Disorders |
|
Neoplasms Neoplasms by Histologic Type Nervous System Diseases Neoplasms, Nerve Tissue Nevi and Melanomas |
